CY1112946T1 - 4-υδροξυβενζομορφανια - Google Patents

4-υδροξυβενζομορφανια

Info

Publication number
CY1112946T1
CY1112946T1 CY20121100677T CY121100677T CY1112946T1 CY 1112946 T1 CY1112946 T1 CY 1112946T1 CY 20121100677 T CY20121100677 T CY 20121100677T CY 121100677 T CY121100677 T CY 121100677T CY 1112946 T1 CY1112946 T1 CY 1112946T1
Authority
CY
Cyprus
Prior art keywords
hydroxybenzomorphania
hydroxybenzomorphs
thiocarboxamide
antipsychotics
anticonvulsants
Prior art date
Application number
CY20121100677T
Other languages
English (en)
Inventor
Mark P Wentland
Original Assignee
Rensselaer Polytechnic Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rensselaer Polytechnic Institute filed Critical Rensselaer Polytechnic Institute
Publication of CY1112946T1 publication Critical patent/CY1112946T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/26—Benzomorphans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/28—Morphinans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom

Abstract

Τα 4-υδροξυβενζομορφάνια τα οποία περιέχουν καρβοξαμίδιο ή θειοκαρβοξαμίδιο στην 3-θέση είναι χρήσιμα ως αναλγητικά, αντιδιαρροϊκά μέσα, αντισπασμωδικά, αντιβηχικά και φάρμακα κατά του εθισμού.
CY20121100677T 2004-11-05 2012-07-31 4-υδροξυβενζομορφανια CY1112946T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62534804P 2004-11-05 2004-11-05
EP10008474A EP2251330B1 (en) 2004-11-05 2005-11-03 4-Hydroxybenzomorphans

Publications (1)

Publication Number Publication Date
CY1112946T1 true CY1112946T1 (el) 2016-04-13

Family

ID=36128632

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100677T CY1112946T1 (el) 2004-11-05 2012-07-31 4-υδροξυβενζομορφανια

Country Status (20)

Country Link
US (7) US7262298B2 (el)
EP (2) EP2251330B1 (el)
JP (3) JP5198067B2 (el)
KR (1) KR101115841B1 (el)
CN (1) CN101090891B (el)
AT (1) ATE557006T1 (el)
AU (1) AU2005304950B2 (el)
BR (1) BRPI0517091B8 (el)
CA (1) CA2587074C (el)
CY (1) CY1112946T1 (el)
DK (1) DK2251330T3 (el)
ES (1) ES2387737T3 (el)
IL (1) IL182983A (el)
MX (1) MX2007005389A (el)
NO (1) NO340204B1 (el)
PL (1) PL2251330T3 (el)
PT (1) PT2251330E (el)
RU (2) RU2480455C2 (el)
SI (1) SI2251330T1 (el)
WO (1) WO2006052710A1 (el)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1944292B9 (en) 2000-10-31 2016-07-06 Rensselaer Polytechnic Institute 8-substituted-2,6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents
SI2251330T1 (sl) * 2004-11-05 2012-09-28 Rensselaer Polytech Inst 4-hidroksibenzomorfani
US7557119B2 (en) 2005-07-21 2009-07-07 Rensselaer Polytechnic Institute Large substituent, non-phenolic opioids
JP2009534472A (ja) 2007-05-04 2009-09-24 マリンクロッド・インコーポレイテッド ６−アルファ−ヒドロキシ−ｎ−アルキル化オピエート類の改良型製造方法
WO2009012005A1 (en) 2007-07-17 2009-01-22 Mallinckrodt Inc. Preparation of n-alkylated opiates by reductive amination
US8263807B2 (en) 2007-08-09 2012-09-11 Rensselaer Polytechnic Institute Quaternary opioid carboxamides
CA2738628C (en) 2008-09-30 2017-07-04 Mallinckrodt Inc. Processes for the selective amination of ketomorphinans
US8946419B2 (en) 2009-02-23 2015-02-03 Mallinckrodt Llc (+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives
AU2009342654B2 (en) * 2009-03-19 2013-09-05 Alkermes Pharma Ireland Limited Morphinan derivatives with high oral bioavailability
WO2010118274A1 (en) * 2009-04-09 2010-10-14 Mallinckrodt Inc. Preparation of 6-keto, 3-alkoxy morphinans
CN102459274B (zh) 2009-06-11 2015-07-15 马林克罗特有限公司 6-酮基去甲吗啡喃通过催化氢转移的还原胺化
PL2440562T3 (pl) 2009-06-11 2017-07-31 Mallinckrodt Llc Otrzymywanie 6-alfa-amino-N-podstawionych morfinanów w wyniku katalitycznego przeniesienia wodoru
ES2729679T3 (es) * 2009-12-04 2019-11-05 Alkermes Pharma Ireland Ltd Derivados de morfinano para el tratamiento de la sobredosis de fármacos
ES2582306T3 (es) 2010-03-22 2016-09-12 Rensselaer Polytechnic Institute Derivados de morfinano que contienen un grupo carboxamida como ligandos de receptores opioides
EP2563793B1 (en) 2010-04-29 2014-10-22 Mallinckrodt LLC Preparation of saturated ketone morphinan compounds having low metal content
JP5728084B2 (ja) 2010-07-08 2015-06-03 アルカーメス ファーマ アイルランド リミテッド 置換モルフィナンの合成のための方法
WO2012027359A1 (en) 2010-08-23 2012-03-01 Alkermes, Inc. Methods for treating antipsychotic-induced weight gain
WO2012138888A1 (en) 2011-04-05 2012-10-11 Alkermes, Inc. Process for the synthesis of quaternary amine compounds
AU2012267780B2 (en) 2011-06-09 2016-09-08 SpecGx LLC Reductive amination of 6-keto morphinans by catalytic hydrogen transfer
CA2840643C (en) 2011-06-29 2017-11-21 Alkermes, Inc. Peripherally acting opioid compounds
WO2013036729A1 (en) 2011-09-08 2013-03-14 Mallinckrodt Llc Production of alkaloids without the isolation of intermediates
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
US8822488B2 (en) 2011-12-15 2014-09-02 Alkermes Pharma Ireland Limited Compositions of buprenorphine and μ antagonists
WO2014190271A2 (en) 2013-05-24 2014-11-27 Alkermes Pharma Ireland Limted Methods for treating depressive symptoms
AU2014268361B2 (en) 2013-05-24 2018-09-06 Alkermes Pharma Ireland Limited Morphan and morphinan analogues, and methods of use
CN110352055A (zh) * 2017-03-02 2019-10-18 株式会社三和化学研究所 酒精使用障碍的治疗药物
CN107089948B (zh) * 2017-04-28 2020-07-17 云南大学 吗吩衍生物及其制备方法和应用
CN111978252A (zh) * 2019-05-21 2020-11-24 复旦大学 手性苯并吗吩烷类衍生物及其制备方法和在药学上的应用
TW202140009A (zh) * 2020-02-13 2021-11-01 大陸商上海翰森生物醫藥科技有限公司 ３－甲醯胺基－４－羥基納曲酮氘代衍生物、其製備方法及其在醫藥上的應用
CN111205151B (zh) * 2020-02-29 2021-03-05 深圳市祥根生物科技有限公司 一种布洛芬杂质i的环保制备方法
EP4243768A1 (en) 2020-11-12 2023-09-20 Alkermes Pharma Ireland Limited Immediate release multilayer tablet

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3957793A (en) 1974-09-20 1976-05-18 Sterling Drug Inc. Hydroxyiminobenzazocines
US4032529A (en) 1974-09-20 1977-06-28 Sterling Drug Inc. Aminomethanobenzazocine intermediates
US4205171A (en) 1976-01-12 1980-05-27 Sterling Drug Inc. Aminomethanobenzazocines and nitromethanobenzazocines
US4373139A (en) 1979-04-30 1983-02-08 Motorola, Inc. Detectors
US4649200A (en) 1986-05-08 1987-03-10 Regents Of The University Of Minnesota Substituted pyrroles with opioid receptor activity
EP0632041A1 (en) 1993-07-01 1995-01-04 Katholieke Universiteit Nijmegen New morphine derivatives having improved analgesic and narcotic properties
ATE229958T1 (de) 1996-01-10 2003-01-15 Glaxosmithkline Spa Heterocyclische kondensierte morphin-derivate
EP1944292B9 (en) * 2000-10-31 2016-07-06 Rensselaer Polytechnic Institute 8-substituted-2,6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents
WO2004007449A1 (en) 2002-07-16 2004-01-22 Rensselaer Polytechnic Institute Process for conversion of phenols to carboxamides via the succinimide esters
SI2251330T1 (sl) * 2004-11-05 2012-09-28 Rensselaer Polytech Inst 4-hidroksibenzomorfani

Also Published As

Publication number Publication date
US20070238748A1 (en) 2007-10-11
US20140148475A1 (en) 2014-05-29
AU2005304950A1 (en) 2006-05-18
JP2008519035A (ja) 2008-06-05
PT2251330E (pt) 2012-07-20
KR20070085723A (ko) 2007-08-27
BRPI0517091B1 (pt) 2019-10-08
JP6058981B2 (ja) 2017-01-11
KR101115841B1 (ko) 2012-03-09
BRPI0517091B8 (pt) 2021-05-25
US20160075658A1 (en) 2016-03-17
US20150011768A1 (en) 2015-01-08
DK2251330T3 (da) 2012-08-06
CA2587074A1 (en) 2006-05-18
RU2415131C2 (ru) 2011-03-27
US20060111384A1 (en) 2006-05-25
JP2016020364A (ja) 2016-02-04
US8680112B2 (en) 2014-03-25
RU2007120759A (ru) 2008-12-10
BRPI0517091A (pt) 2008-09-30
IL182983A0 (en) 2007-08-19
EP1817291A1 (en) 2007-08-15
RU2480455C2 (ru) 2013-04-27
AU2005304950B2 (en) 2010-12-09
PL2251330T3 (pl) 2012-12-31
US20240092740A1 (en) 2024-03-21
ATE557006T1 (de) 2012-05-15
IL182983A (en) 2012-06-28
NO340204B1 (no) 2017-03-20
JP5198067B2 (ja) 2013-05-15
EP2251330B1 (en) 2012-05-09
CA2587074C (en) 2012-09-04
ES2387737T3 (es) 2012-10-01
CN101090891B (zh) 2012-08-01
NO20072839L (no) 2007-08-03
RU2010147915A (ru) 2012-05-27
JP2013067636A (ja) 2013-04-18
CN101090891A (zh) 2007-12-19
US7262298B2 (en) 2007-08-28
WO2006052710A1 (en) 2006-05-18
US20130231361A1 (en) 2013-09-05
EP2251330A1 (en) 2010-11-17
MX2007005389A (es) 2007-12-07
SI2251330T1 (sl) 2012-09-28
US8802655B2 (en) 2014-08-12

Similar Documents

Publication Publication Date Title
CY1112946T1 (el) 4-υδροξυβενζομορφανια
CY1118480T1 (el) Παραγωγα toy uk-2a
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
CY2013004I1 (el) Προϊοντα συζευξης auristatin και χρηση αυτων για θεραπεια καρκινου, αυτοανοσης ασθενειας ή μολυσματωδους ασθενειας
ATE447561T1 (de) Substituierte aryl 1,4-pyrazin derivate
NO20044039L (no) Konjugatorer av terapeutiske eller cytotoksiske midler og biologisk aktive peptider.
DE60010098D1 (de) 28-epirapaloge
CY1109468T1 (el) Χρησεις ανταγωνιστων της il-23. σχετικα αντιδραστηρια
NO20053556D0 (no) Polymerkonjugater av interferon-beta med forbedret biologisk potens.
BR0212250B1 (pt) produto de cuidado pessoal.
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
DE60225563D1 (de) 4-amino-6-phenyl-pyrroloä2,3-düpyrimidin derivate
DE60231682D1 (de) Naturkautschuk-Masterbatch dessen Herstellungsverfahren, und Naturkautschukzusammensetzung
ATE319684T1 (de) Sulfonamidderivate, deren herstellung und deren verwendung als medikamente
DE602004024770D1 (de) Substituierte 8-perfluoro-6,7,8,9-tetrahydropyrimido-(1,2a) pyrimidin-4-on derivate
CY1112591T1 (el) Απο του στοματος φαρμακοτεχνικες μορφες της κλαντριβινης
DE602006012410D1 (de) Kosmetische und/oder dermatologische Zusammensetzung mit Bornitrid
ATE355104T1 (de) Haarbehandlungsmittel
DE60142913D1 (de) Arzneilösungen enthaltend modafinilverbindungen
UY28344A1 (es) Nuevos compuestos
DE60334632D1 (de) Mechanolumineszenzstoff und dessen herstellung
SI1545710T1 (sl) Uporaba N-(3-metoksi-5-metilpirazin-2-il)-2-(4-(1,3,4-oksadiazol-2-il)fenil) piridin-3-sulfonamida v zdravljenju raka
DE60114039D1 (de) Kautschukzusammensetzungen und vulkanisate einschliesslich verzweigter kammpolymere
TR200302193T4 (tr) Kombinasyon kemoterapisi.
DE60316668D1 (de) Kautschukzusammensetzung, vulkanisierbare kautschukzusammensetzung und vulkanisat